CD4 and myeloid sarcoma: The hUC‐MSCs treatment (MSCT) groups were coculturing hUC‐MSCs to CD4+ T cells from moderate and severe SLE (SLE‐MS) groups for 72 h at ratios of 1:25 (T1), 1:10 (T2), and 1:5 (T3).